Home Stock

Stock Research: GlaxoSmithKline Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

GlaxoSmithKline Pharmaceuticals

NSI:GLAXO INE159A01016
51
  • Value
    8
  • Growth
    72
  • Safety
    Safety
    85
  • Combined
    23
  • Sentiment
    46
  • 360° View
    360° View
    51
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company manufacturing, distributing, and trading in pharmaceuticals. The company operates in vaccines, specialty, and general medicine, with popular brands including Augmentin, Calpol, Shingrix, and Nucala. It operates primarily in India. In the last fiscal year, the company had 3113 employees, a market cap of $6242 millions, profits of $262 millions, and revenue of $439 millions.

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Liquidity
Country United Kingdom
Industry Pharmaceuticals
Size Medium
Website india-pharma.gsk.com
Index
GlaxoSmithKline Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 17 29
Growth
72 87 25 31
Safety
Safety
85 77 79 65
Sentiment
46 77 32 1
360° View
360° View
51 79 16 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
59 74 43 13
Opinions Change
77 94 50 50
Pro Holdings
n/a 54 77 49
Market Pulse
60 46 7 5
Sentiment
46 77 32 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
8 13 17 29
Growth
72 87 25 31
Safety Safety
85 77 79 65
Combined
23 77 19 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
17 1 12 16
Price vs. Earnings (P/E)
9 19 12 20
Price vs. Book (P/B)
3 5 10 7
Dividend Yield
53 56 74 76
Value
8 13 17 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
46 44 28 10
Profit Growth
78 92 45 88
Capital Growth
90 65 25 7
Stock Returns
28 77 71 53
Growth
72 87 25 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
87 92 90 82
Refinancing
23 18 26 22
Liquidity
94 92 92 80
Safety Safety
85 77 79 65

Similar Stocks

Discover high‑ranked alternatives to GlaxoSmithKline Pharmaceuticals and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Grainger

LSE:GRI
Country: United Kingdom
Industry: Real Estate: Operating Services
Size: Medium
Full Stock Analysis

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The only above-average rank is Safety. All other ranks (Value, Growth, and Sentiment) are below average. As Safety is the least critical rank, there are few positive facts to support this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews